Xiangxue Pharmaceutical Launches Phase II Clinical Trial of China's First TCR-T Cell Therapy Product TAEST16001

Reporters Xiao Wei and Zhang Junbing (Intern)

On July 8, 2022, Xiangxue Life Sciences Technology (Guangdong) Co., Ltd. ("Xiangxue Life Sciences"), a subsidiary of Xiangxue Pharmaceutical, held a kick-off meeting with the Sun Yat-sen University Cancer Center for a multi-center, open-label, single-arm, Phase II clinical study of the cell therapy product TAEST16001 in the treatment of advanced soft tissue sarcoma, marking a new phase of clinical research for China's first TCR-T cell therapy product.

TAEST16001, independently developed by Xiangxue Life Sciences, is China's first TCR-T cell immunotherapy product to receive an IND approval. In Phase I clinical research, the safety and efficacy of TAEST16001 were preliminarily validated, strongly supporting the continuation into Phase II clinical research for advanced soft tissue sarcoma. The Phase I clinical study of TAEST16001 was presented as an oral report at the 2022 ASCO Annual Meeting, where its safety and efficacy results were comparable to those of products targeting the same indication from renowned international pharmaceutical companies, drawing significant global attention.

Currently, Xiangxue Life Sciences has two products that have received IND approval in China. The first product, TAEST16001, is for the treatment of soft tissue sarcoma and is currently undergoing Phase II clinical trials. The second product, TAEST1901, targets primary liver cancer and will soon initiate Phase I clinical trials.

(Editor: Zhang Wei)